Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
105.42
+5.12 (5.10%)
At close: Nov 21, 2025, 4:00 PM EST
106.55
+1.13 (1.07%)
After-hours: Nov 21, 2025, 7:59 PM EST
Guardant Health Employees
As of December 31, 2024, Guardant Health had 2,021 total employees, including 1,999 full-time and 22 part-time employees. The number of employees increased by 242 or 13.60% compared to the previous year.
Employees
2,021
Change (1Y)
242
Growth (1Y)
13.60%
Revenue / Employee
$446,595
Profits / Employee
-$197,323
Market Cap
13.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,021 | 242 | 13.60% |
| Dec 31, 2023 | 1,779 | -14 | -0.78% |
| Dec 31, 2022 | 1,793 | 420 | 30.59% |
| Dec 31, 2021 | 1,373 | 509 | 58.91% |
| Dec 31, 2020 | 864 | 242 | 38.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GH News
- 2 days ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 4 days ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 10 days ago - Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access - Business Wire
- 12 days ago - Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring - Business Wire
- 15 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response - Business Wire
- 17 days ago - Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients - Business Wire